Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (8871)	6/2/1998 8:52:00 AM
From: Zebra 365	Read Replies (1) \| Respond to of 23519

The agency said Viagra's active substance, sildenafil citrate, should not be prescribed to patients who are taking nitrates, have recently had a stroke or heart attack or suffer from low blood pressure, severe heart or liver problems or certain inherited eye diseases. It added that it should not be used by women.>> Hmmm Sounds like %50 of the true ED market is going to be excluded, as the paper presented yesterday suggested that 70% of men with organic ED had it based on vascular disease. Zebra

To: Frostman who wrote (8871)	6/2/1998 8:54:00 AM
From: RT	Respond to of 23519

Frostman <<The agency said Viagra's active substance, sildenafil citrate, should not be prescribed to patients who are taking nitrates, have recently had a stroke or heart attack or suffer from low blood pressure, severe heart or liver problems or certain inherited eye diseases.>> Doesn't that just about eliminate all the real ED patients who need Viagara for health reasons? RT

To: Frostman who wrote (8871)	6/2/1998 8:55:00 AM
From: VLAD	Read Replies (2) \| Respond to of 23519

Frosty and all longs, We have slowly bled for a long time now. Let's see some short blood on the street today. Could this be the start of our long waited short squeeze? Anyone out there care to help me in my campaign to see legal and fair trading in Vivus stock? Call the NASD at 202-728-8805. I already did my part with the SEC. Now if the NASD gets a lot of complaints they will do an internal investigation which may very well prevent this stock from bleeding out whenever is shows strength due to shorting of nonavailable Vivus stock.